Women with metastatic breast cancer have extended survival if their physicians simply combine anastrazole (Arimidex, AstraZeneca) and fulvestrant (Faslodex, AstraZeneca), a study presented here at the 34th Annual San Antonio Breast Cancer Symposium shows.
Women taking the 2 drugs in combination lived more than 6 months longer than women who took the drugs sequentially, according to the researchers who presented their findings....
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.